Lanifibranor is a chemical compound that acts as a pan-peroxisome proliferator-activated receptor (PPAR) agonist, targeting PPAR-alpha, PPAR-beta, and PPAR-gamma simultaneously. It is being investigated in clinical trials for nonalcoholic steatohepatitis (NASH) and has shown potential to improve both steatohepatitis and fibrosis.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 927961-18-0
Flomoxef sodium
pharmaceutical raw material
3-[[4-[methyl-[2-(4-methyl-1-piperazinyl)-1-oxoethyl]amino]anilino]-phenylmethylidene]-2-oxo-1H-indole-6-carboxylic acid methyl ester
pharmaceutical raw material
Canagliflozin hemihydrate
pharmaceutical raw material
Seladelpar lysine dihydrate
pharmaceutical raw material
4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloroindol-2-yl]butanoic acid
OQDQIFQRNZIEEJ-UHFFFAOYSA-N
C1=CC2=C(C=C1S(=O)(=O)N3C4=C(C=C(C=C4)Cl)C=C3CCCC(=O)O)SC=N2